Semaglutide Research

Qiao Y, Zhou F, Mao T, Gao L

Glucose-dependent insulinotropic polypeptide (GIP), once the overlooked sibling of the incretin family, is now experiencing a research renaissance. Historically, its therapeutic development was hindered by a seemingly diminished insulinotropic effect in type 2 diabetes (T2DM), its paradoxical sti...

Chen Q, Chen T, Lin W, Chen X

To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection.This study was structured according to the "A...

Schaefer LM, Kerver GA, Allison KC, Kohoutek B, Steffen KJ

Limited available data indicate that glucagon-like peptide-1 (GLP-1) medications may significantly reduce weight and binge-eating symptoms among patients with binge-eating disorder. However, experts express concern about the potential for GLP-1 medications to cause unintended harm or be misused a...

Smith BL, May A, Lalani F, Hasham S, Presnell AA

Obesity is a chronic, multifactorial disease associated with significant metabolic, physical, and psychosocial complications. Although advances in pharmacologic therapy-particularly glucagon-like peptide-1 (GLP-1)-based agents-have expanded treatment options, challenges persist in the effective m...

Herrera HO, Bordeaux JS

Turinsky AL, Hanafi N, Said A, Kinnear C, Lesurf R, López-Guillén JL et al.

Pediatric cardiomyopathy is a major cause of diastolic heart failure; yet, its mechanisms remain unclear. Global myocardial transcriptomic and blood lipidomic profiling revealed a distinct metabolic signature of diastolic dysfunction marked by dysregulated lipid signaling. A machine learning mode...

Tuttle KR, Mann JFE, Mayrdorfer MM, Rayner B, Pugliese G, Pratley RE et al.

Semaglutide improved kidney and overall survival in participants with type 2 diabetes (T2D) and chronic kidney disease (CKD) in the FLOW trial. The aim of the present analyses was to quantify these benefits across broad strata of CKD severity.FLOW was a double-blind, randomized, placebo-controlle...

Ando K, Takenoshita M, Wei MT

A 58-year-old man scheduled for an elective upper endoscopy followed standard preprocedural fasting guidelines and withheld one weekly dose of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA). Despite these measures, substantial residual gastric contents led to procedure...

Wang N, Guo H, Song L, Wang J, Hu S, Wang M et al.

To investigate the metabolic mechanisms underlying weight regain (WR) after semaglutide withdrawal in females with obesity, focusing on gut microbiota, bile acid metabolism, and central nervous system regulation.In a prospective, single-arm interventional study, 28 women with obesity finished 36-...

Thandi P, Pradhan A, Behera SK

The intricate interplay of physiological, psychological, and social factors presents considerable challenges in addressing heart failure. It is imperative to comprehend the epidemiology and pathophysiology, identify predictors and their influence on clinical outcomes, and effectively utilize the ...

Makkena HB

Background The rapid adoption of incretin-based therapies for obesity has raised questions regarding their comparative safety profiles. While the gynecological safety of glucagon-like peptide-1 (GLP-1) receptor agonists is documented, the potential risks associated with dual glucose-dependent ins...

Kamath S, Chan NSL, Joyce P

Glucagon-like peptide-1 (GLP-1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research. Mounting evidence suggests that the gut microbiot...

Ulrich FS, Napoli N, Nielsen MF, Burden AM

Real-world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP-1 receptor agonist (GLP-1RA) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, obesity status, cardiovascular disease (CVD) history, ...

Biasin M, Stratinaki M, Cordioli N, Armani I, De Giovanni S, Aletras G et al.

Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated cardiovascular benefit in patients with type 2 diabetes mellitus (T2DM) and established atherosclerotic disease. Its role in the immediate postacute coronary syndrome (ACS) setting, however, remains unexplored. This study e...

Michalon R, Planche V, Lemoine M, Keuck L, Villain N

Uhrenholt N, Ganeshalingam A, Arnfred S, Gæde P, Pedersen AK, Larsen PV et al.

People with schizophrenia experience markedly reduced health-related quality of life (QoL), partly driven by obesity and metabolic dysregulation. Glucagon-like peptide-1 receptor agonists such as semaglutide induce substantial weight loss in the general population and in patients receiving antips...

Alhalabi H, Borschel L, Le Foll C, Thomas A, Bally L, Thevis M et al.

Peptide hormone-based weight-loss therapeutics have gained increasing attention, driven amongst other reasons, by the clinical and commercial success of semaglutide. Their increasing accessibility raises concerns about their potential misuse in sports, especially in disciplines where weight manag...

Zahed M, Alesawy AF, Elkohail A, Ghazi A, Fell A, Hashem M et al.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are emerging as a cornerstone in the management of type 2 diabetes and obesity. The perioperative implications of GLP-1RAs in orthopaedic surgery are a growing area of interest; however, their effects in patients undergoing foot and ankle surge...

Kahles F, Birkenfeld AL, Marx N

The incretin hormone glucagon-like peptide-1 (GLP-1) exerts potent effects on glucose metabolism, prompting the development of therapeutic strategies that enhance activity of the GLP-1 receptor (GLP-1R) pathway. Inhibitors of dipeptidyl peptidase 4 (DPP-4) prolong the half-life of endogenous GLP-...

Patil S, Jha N, Jha MK

Substance use disorders (SUDs) are widely prevalent and associated with high morbidity and mortality. Current treatments have limited efficacy and there are no United States Food and Drug Administration (FDA)-approved treatments for several SUDs (such as methamphetamine, cocaine, and cannabis use...